Rapid Point-of-Care RNA Diagnostic for Dengue Infection CrossLife Technologies Inc. Project Summary/Abstract Dengue viruses (DENV) are one of the most dangerous and significant pathogens in the world, and there are 230 million cases of dengue virus infections per year, mostly in Latin America and Southeast Asia. These mosquito-borne viruses cause periodic explosive epidemics in many tropical and sub-tropical countries. CrossLife technologies' dengue diagnostic is being developed to detect dengue infection early at the point-of-care so that patients can be treated effectively. Early and rapid detection of dengue virus (DENV) infection during the febrile period is crucial for proper patient management and containment of the disease. However, current methods for early detection of dengue involve the use of RT-PCR instruments in the laboratory, which may not be available in areas where dengue is endemic, and which may be too slow. CrossLife Technologies proposed to develop a Template Assisted Rapid Assay (TARA) diagnostics for detection of dengue viruses in human blood. TARA dengue diagnostic will detect dengue in 30 minutes on a paper strip at the point-of-care (POC) so that patients can be treated rapidly and at low cost. This innovative technology will provide PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.
Rapid Point-of-Care RNA Diagnostic for Dengue Infection CrossLife Technologies Inc. Project Narrative Dengue fever is considered to be one of the most significant public health problems with a huge economic impact, with 230 million infections per year world-wide. We propose the development and commercialization of a rapid, point-of-care diagnostic for early detection of dengue without the need for laboratory instrumentation which may not be available in many resource-limited settings where dengue is endemic.
